JP2011503103A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503103A5 JP2011503103A5 JP2010533304A JP2010533304A JP2011503103A5 JP 2011503103 A5 JP2011503103 A5 JP 2011503103A5 JP 2010533304 A JP2010533304 A JP 2010533304A JP 2010533304 A JP2010533304 A JP 2010533304A JP 2011503103 A5 JP2011503103 A5 JP 2011503103A5
- Authority
- JP
- Japan
- Prior art keywords
- coor
- optionally substituted
- alkyl
- compound
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- -1 4-piperidyl Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 125000002577 pseudohalo group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 102000019355 Synuclein Human genes 0.000 claims 1
- 108050006783 Synuclein Proteins 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000006178 methyl benzyl group Chemical group 0.000 claims 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 0 *c1c[n](*)c2nc(*)nc(*)c12 Chemical compound *c1c[n](*)c2nc(*)nc(*)c12 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98628207P | 2007-11-07 | 2007-11-07 | |
| PCT/US2008/082909 WO2009062118A2 (en) | 2007-11-07 | 2008-11-07 | Modulation of protein trafficking |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503103A JP2011503103A (ja) | 2011-01-27 |
| JP2011503103A5 true JP2011503103A5 (enExample) | 2013-01-17 |
Family
ID=40521617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533304A Withdrawn JP2011503103A (ja) | 2007-11-07 | 2008-11-07 | タンパク質輸送の調節方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100331297A1 (enExample) |
| EP (1) | EP2217239A2 (enExample) |
| JP (1) | JP2011503103A (enExample) |
| CN (1) | CN101917999A (enExample) |
| AU (1) | AU2008323694A1 (enExample) |
| BR (1) | BRPI0820342A2 (enExample) |
| CA (1) | CA2705303A1 (enExample) |
| EA (1) | EA201070572A1 (enExample) |
| WO (1) | WO2009062118A2 (enExample) |
| ZA (1) | ZA201003725B (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1831225A2 (en) | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
| WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
| CA2740885C (en) * | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| DE102009004245A1 (de) * | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
| EP2845856A1 (en) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| DK2516434T3 (en) | 2009-12-23 | 2015-08-31 | Takeda Pharmaceutical | FUSED HETEROAROMATIC PYRROLIDINONS AS SICK INHIBITORS |
| AU2010339444A1 (en) | 2009-12-30 | 2012-07-19 | Arqule, Inc. | Substituted pyrrolo-aminopyrimidine compounds |
| JP2013518114A (ja) * | 2010-01-27 | 2013-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾロピリミジンキナーゼ阻害剤 |
| MX336731B (es) | 2010-01-28 | 2016-01-28 | Harvard College | Composiciones y metodos para potenciar la actividad de proteasoma. |
| CA2794153C (en) | 2010-03-25 | 2018-01-02 | Glaxosmithkline Llc | Substituted indoline derivatives as perk inhibitors |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| US8642606B2 (en) * | 2010-09-29 | 2014-02-04 | Plexxikon Inc. | ZAP-70 active compounds |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| CA2834049C (en) | 2011-04-25 | 2018-05-22 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| RS58718B1 (sr) | 2011-05-12 | 2019-06-28 | Proteostasis Therapeutics Inc | Regulatori proteostaze |
| WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| EA201490265A1 (ru) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| EP2548878A1 (en) * | 2011-07-21 | 2013-01-23 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands |
| UA121539C2 (uk) | 2011-09-02 | 2020-06-25 | Інсайт Холдинґс Корпорейшн | Гетероцикліламіни як інгібітори рі3к |
| MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| MX2015003874A (es) | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
| EP2911671B1 (en) * | 2012-10-25 | 2018-06-27 | Usher III Initiative | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| JP6290910B2 (ja) * | 2012-10-25 | 2018-03-07 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 |
| ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
| US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| EP3290421B1 (en) | 2013-02-22 | 2019-01-02 | Pfizer Inc | Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak) |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| WO2015171527A1 (en) * | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
| CN106459048A (zh) * | 2014-05-14 | 2017-02-22 | 辉瑞公司 | 吡唑并吡啶类和吡唑并嘧啶类 |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| EP3180344B1 (en) | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| CN104530151A (zh) * | 2015-01-15 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 一种含硝基苯s-葡萄糖苷结构的化合物及其用途 |
| CN104530153A (zh) * | 2015-01-15 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 一类苯基s-葡萄糖苷衍生物、其制备方法和在医药上的用途 |
| UA122332C2 (uk) | 2015-02-27 | 2020-10-26 | Інсайт Корпорейшн | Солі інгібітора pi3k і способи їх отримання |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| KR20180015160A (ko) * | 2015-06-22 | 2018-02-12 | 오노 야꾸힝 고교 가부시키가이샤 | Brk 저해 화합물 |
| CN107922396B (zh) * | 2015-07-20 | 2022-08-05 | 建新公司 | 集落刺激因子-1受体(csf-1r)抑制剂 |
| LV15201B (lv) | 2015-08-31 | 2017-07-20 | Latvijas Organiskās Sintēzes Institūts | Ibrutiniba izejvielas iegūšanas paņēmiens |
| CN105198887B (zh) * | 2015-09-23 | 2017-07-28 | 上海泰坦科技股份有限公司 | 具有生物活性吡唑并[3,4‑d]嘧啶类试剂的合成工艺 |
| PL3359541T3 (pl) * | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| US20170100374A1 (en) * | 2015-10-09 | 2017-04-13 | AbbVie S.à.r.l. | Potentiator-corrector combinations useful in the treatment of cystic fibrosis |
| GB201521109D0 (en) * | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| CN109153642B (zh) * | 2016-02-12 | 2022-05-17 | 法玛西斯有限公司 | 赖氨酰氧化酶的吲哚及氮杂吲哚卤化烯丙胺衍生物抑制剂及其用途 |
| JP6971997B2 (ja) * | 2016-02-15 | 2021-11-24 | アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・（インセルム） | 個体における尿中シュウ酸塩濃度を低下させるための、スチリペントール及びその誘導体の使用 |
| WO2017161344A1 (en) * | 2016-03-17 | 2017-09-21 | The Regants Of The University Of California | Compositions and methods for treating parasitic diseases |
| CN107513068A (zh) * | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
| SG11201901197PA (en) | 2016-08-24 | 2019-03-28 | Arqule Inc | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
| IL248028B (en) * | 2016-09-25 | 2022-02-01 | Univ Bar Ilan | Wasp-protecting small molecules, compositions, methods and uses thereof in the treatment of wiskott-aldrich syndrome and x-linked thrombocytopenia |
| MX2021012639A (es) * | 2016-11-18 | 2022-10-03 | Cystic Fibrosis Found | Pirrolopirimidinas como potenciadores de cftr. |
| KR20190084991A (ko) | 2016-11-28 | 2019-07-17 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피라졸로-헤테로아릴 유도체, 이의 제조 방법 및 의학적 용도 |
| WO2018112149A1 (en) * | 2016-12-16 | 2018-06-21 | Cystic Fibrosis Foundaton Therapeutics Inc. | Bycyclic heteroaryl derivatives as cftr potentiators |
| TW201837040A (zh) * | 2017-03-15 | 2018-10-16 | 美商微拉製藥公司 | Cdpk1抑制劑及與其相關之組合物及方法 |
| EP3668875A4 (en) * | 2017-08-17 | 2020-12-30 | Vyera Pharmaceuticals, LLC | CDPK1 INHIBITOR, ASSOCIATED COMPOSITIONS AND PROCESSES |
| FR3075795A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
| FR3075794A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
| EP3740490A1 (en) * | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CN110526917B (zh) * | 2018-05-25 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法 |
| JP2021526520A (ja) * | 2018-05-25 | 2021-10-07 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | ピラゾロヘテロアリール誘導体の塩酸塩の結晶形および調製方法 |
| CN110526918B (zh) * | 2018-05-25 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种吡唑并杂芳基类衍生物的晶型及制备方法 |
| MX2020012826A (es) | 2018-06-01 | 2021-03-09 | Incyte Corp | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). |
| WO2019233994A1 (en) | 2018-06-04 | 2019-12-12 | Exscientia Ltd | Pyrazolopyrimidine compounds as adenosine receptor antagonists |
| JP2022500422A (ja) * | 2018-09-18 | 2022-01-04 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 骨格筋調節のためのｓｒｃ阻害剤化合物、それらの方法及び使用 |
| WO2020061279A1 (en) * | 2018-09-19 | 2020-03-26 | Vyera Pharmaceuticals, LLC | Cdpk1 inhibitors, compositions, and methods related thereto |
| KR102706457B1 (ko) | 2018-12-06 | 2024-09-11 | 한국화학연구원 | Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도 |
| JP7566753B2 (ja) * | 2019-01-03 | 2024-10-15 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料 |
| WO2022011091A1 (en) | 2020-07-09 | 2022-01-13 | Usher Iii Initiative, Inc. | Treatment of cancer, inflammatory diseases and autoimmune diseases |
| PY2193067A (es) | 2020-10-23 | 2022-06-20 | Ildong Pharmaceutical Co Ltd | Compuestos moduladores del cftr, composiciones y usos de estos |
| WO2022133480A1 (en) * | 2020-12-18 | 2022-06-23 | Ikena Oncology, Inc. | Aryl hydrocarbon receptor (ahr) agonists and uses thereof |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
| AU2022230057A1 (en) * | 2021-03-03 | 2023-09-28 | Instytut Biologii doswiadczalnej imienia Marcelego Nenckiego Polskiej Akademii Nauk | Inhibitor of protein kinase d for use in prevention or treatment of hyperlipidemia |
| CN116514845B (zh) * | 2022-01-22 | 2026-03-10 | 轩竹生物科技股份有限公司 | Usp1抑制剂及其用途 |
| ES3038124T3 (en) * | 2023-05-09 | 2025-10-09 | Molecular Horizon S R L | Phenylpyrazole insecticide compounds and compositions |
| WO2025121320A1 (ja) * | 2023-12-04 | 2025-06-12 | 国立大学法人山口大学 | 多発性嚢胞腎の予防又は治療剤 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6342501B1 (en) * | 1994-02-25 | 2002-01-29 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d] pyrimidines as antiviral agents |
| CN1523991A (zh) * | 2001-08-10 | 2004-08-25 | ��˹��ŵ�� | 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途 |
| US20030180924A1 (en) * | 2002-03-22 | 2003-09-25 | Desimone Robert W. | Formulation of certain pyrazolo [3,4,-d] pyrimidines as kinase modulators |
| UA80171C2 (en) * | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| MXPA05012619A (es) * | 2003-05-21 | 2006-02-08 | Univ Texas | Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca. |
| US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| WO2005112936A1 (en) * | 2004-05-14 | 2005-12-01 | The Regents Of The University Of Michigan | Compositions and methods relating to protein kinase inhibitors |
| US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
| EP1831225A2 (en) * | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
| US20090270431A1 (en) * | 2005-10-19 | 2009-10-29 | The University Of Georgia Research Foundation | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections |
| EP2007373A4 (en) * | 2006-03-29 | 2012-12-19 | Foldrx Pharmaceuticals Inc | INHIBITION OF ALPHA SYNUCLEINE TOXICITY |
| WO2008147687A1 (en) * | 2007-05-21 | 2008-12-04 | Mayo Foundation For Medical Education And Research | Treating pancreatitis |
-
2008
- 2008-11-07 CN CN200880124202XA patent/CN101917999A/zh active Pending
- 2008-11-07 CA CA2705303A patent/CA2705303A1/en not_active Abandoned
- 2008-11-07 JP JP2010533304A patent/JP2011503103A/ja not_active Withdrawn
- 2008-11-07 WO PCT/US2008/082909 patent/WO2009062118A2/en not_active Ceased
- 2008-11-07 EP EP08848219A patent/EP2217239A2/en not_active Withdrawn
- 2008-11-07 BR BRPI0820342-3A patent/BRPI0820342A2/pt not_active IP Right Cessation
- 2008-11-07 EA EA201070572A patent/EA201070572A1/ru unknown
- 2008-11-07 AU AU2008323694A patent/AU2008323694A1/en not_active Abandoned
- 2008-11-07 US US12/741,992 patent/US20100331297A1/en not_active Abandoned
-
2010
- 2010-05-25 ZA ZA2010/03725A patent/ZA201003725B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2475478C2 (ru) | Соединения для лечения пролиферативных расстройств | |
| JP2014511869A5 (enExample) | ||
| JP2017537882A5 (enExample) | ||
| RU2009133794A (ru) | Гербициды на основе замещенного n-оксида пиридина | |
| JP2009504763A5 (enExample) | ||
| JP2018502101A5 (enExample) | ||
| MY145465A (en) | Diaminopyrimidines as p2x3 and p2x2/3 antagonists. | |
| RU2018120153A (ru) | Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью | |
| JP2016512203A5 (enExample) | ||
| BR112013031121A2 (pt) | composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento | |
| JP2005502661A5 (enExample) | ||
| JP2011515398A5 (enExample) | ||
| JP2009532486A5 (enExample) | ||
| RU2007134380A (ru) | Антибактериальные производные пиперидина | |
| ME02532B (me) | Jedinjenja beta-laktama supstituisana amidinom, njihovo dobijanje i upotreba kao antibakterijskih sredstava | |
| JP2015522650A5 (enExample) | ||
| NO20072515L (no) | 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav | |
| JP2017525668A5 (enExample) | ||
| JP2019507179A5 (enExample) | ||
| JP2016534124A5 (enExample) | ||
| JP2009516697A5 (enExample) | ||
| BRPI0506765A (pt) | composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição | |
| RU2015121037A (ru) | Производные фенилэтилпиридина в качестве ингибиторов pde-4 | |
| JP2006501201A5 (enExample) | ||
| JP2011516511A5 (enExample) |